Review Article

Genetic Mutations and Mitochondrial Toxins Shed New Light on the Pathogenesis of Parkinson’s Disease

Shigeto Sato and Nobutaka Hattori

Department of Neurology, Juntendo University School of Medicine, Tokyo 113-8421, Japan

Correspondence should be addressed to Nobutaka Hattori, nhattori@juntendo.ac.jp

Received 11 April 2011; Revised 2 June 2011; Accepted 12 June 2011

Academic Editor: Honglei Chen

Copyright © 2011 S. Sato and N. Hattori. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

The cellular abnormalities in Parkinson’s disease (PD) include mitochondrial dysfunction and oxidative damage, which are probably induced by both genetic predisposition and environmental factors. Mitochondrial dysfunction has long been implicated in the pathogenesis of PD. The recent discovery of genes associated with the etiology of familial PD has emphasized the role of mitochondrial dysfunction in PD. The discovery and increasing knowledge of the function of PINK1 and parkin, which are associated with the mitochondria, have also enhanced the understanding of cellular functions. The PINK1-parkin pathway is associated with quality control of the mitochondria, as determined in cultured cells treated with the mitochondrial uncoupler carbonyl cyanide m-chlorophenylhydrazone (CCCP), which causes mitochondrial depolarization. To date, the use of mitochondrial toxins, for example, 1-methyl-4-phenyl-tetrahydropyridine (MPTP) and CCCP, has contributed to our understanding of PD. We review how these toxins and familial PD gene products are associated with and have enhanced our understanding of the role of mitochondrial dysfunction in PD.

1. Introduction

Parkinson’s disease (PD) is the most common neurodegenerative movement disorder, affecting 1% of the population above the age of 60. The classical form of the disease is characterized clinically by rigidity, resting tremor, bradykinesia, and postural instability. In addition to these four cardinal symptoms, many nonmotor symptoms frequently appear in PD, such as cognitive impairment, hallucinations, delusion, behavioral abnormalities, depression, disturbances of sleep and wakefulness, loss of smell, pain, and autonomic dysfunctions such as constipation, hypotension, urinary frequency, impotence, and sweating. The pathological hallmarks of PD are the preferential loss of dopaminergic neurons of the substantia nigra (SN) pars compacta and formation of Lewy bodies. Exposure to environmental factors including mitochondrial toxin like 1-methyl-4-phenyl-tetrahydropyridine (MPTP) produces selective degeneration of dopaminergic neurons in SN and results in an irreversible Parkinsonism [1–3]. The active metabolite of MPTP, 1-methyl-4-phenylpyridinium ion (MPP+), is an inhibitor of complex I, and it accumulates in dopaminergic neurons because it is actively transported via dopamine transporter (DAT) [4–6]. The inhibition of the electron transport induces oxidative damage by increasing the formation of reactive oxygen species (ROS) and leads to further mitochondrial dysfunction [7]. These findings were supported by evidence of oxidative damage including an increase in lipid peroxide [8], decrease in glutathione [9], increase in hydroxynonenal-modified proteins [10], and increase in 8-hydroxy-deoxy guanine [11] in SN. ROS impair mitochondrial proteins, further aggravating mitochondrial function. Ultimate outcomes are dissipation of mitochondrial membrane potential and the release of cytochrome c into the cytoplasm and activation of the apoptotic cascade. A biochemical link between MPTP toxicity and Parkinsonism was confirmed with the finding of low levels of complex I in the SN, skeletal muscle, and platelets in patients with PD [12, 13]. In contrast, it remains unknown whether this systemic deficiency of complex I is crucially related to dopaminergic cell loss in PD. Rats administered rotenone (an inhibitor of complex I) developed neuronal degeneration and formation of synuclein-positive
inclusions; however, the degree of complex I inhibition was not severe enough to induce brain mitochondrial dysfunction [14]. Although inhibition of complex I and production of free radical result in increased oxidative stress, it remains unclear whether such dysfunction is a primary or a secondary process in the pathogenesis of the disease.

2. Involvement of Two Mitochondrial Toxic Pathways in Synuclein, DJ-1, and Parkin Mice Model

Several mutations of the synuclein gene (SNCA) at the PARK1 locus induce autosomal dominant Parkinsonism. Three missense mutations: A53T [15], A30P [16], and E46K [17], duplications [18–21], and triplications [22, 23] of SNCA have so far been described. Triplications are associated with Parkinsonism and dementia, and the age of onset is younger than the other mutations, and the neuropathological changes are those of diffuse Lewy body disease. Regarding the pathogenesis of PARK1-linked PD, accumulation of normal synuclein is likely to predispose nigral neurons for protofibril formation. Toxicity associated with increased synuclein expression is an important cellular event that enhances the genetic predisposition to sporadic PD. At present, indirect evidence suggests a relationship between synuclein and oxidative stress, including protein carbonylation and lipid peroxidation. Furthermore, synuclein-deficient mice were found to have striking resistance to MPTP-induced degeneration of dopaminergic neurons, and this resistance appeared to be related to failure of the toxin itself. Interestingly, there was dissociation in the resistance between MPTP-and rotenoneduced cell vulnerability of synuclein-null dopaminergic neurons [24]. This result suggests that MPTP associates with synuclein through another pathway independent of complex I inhibition (mitochondrial dysfunction), to finally induce dopaminergic cell death. Several mutations of the DJ-1 gene at the PARK7 locus induce autosomal recessive Parkinsonism [25]. Clinical phenotype is characterized by an onset in the mid-thirties, good levodopa response, and slow disease progression. Several lines of evidence suggest that it plays a role in the oxidative stress response [26, 27]. Subcellular localization studies have shown DJ-1 to be present in the cytosol, mitochondria, and nucleus [26, 28, 29]. Junn et al. [30] showed that in response to oxidative stress, some of the DJ-1 protein is translocated from its major cytosolic pool to mitochondria and nucleus. DJ-1 null mice are vulnerable to MPTP [31]. On the other hand, Thomas et al. [32] reported that the susceptibility of SN to MPTP in mice is independent of parkin activity. In short, the absence of parkin does not seem to increase the vulnerability of dopaminergic neurons to MPTP intoxication. Another study also found that oxidative stress, including MPTP, altered parkin solubility, causing parkin aggregation, thereby suggesting parkin dysfunction as a pathogenic mechanism of sporadic PD [33].

3. Functional Interplay between PINK1 and Parkin to Maintain Mitochondrial Integrity

Many mutations of the parkin gene at the PARK2 locus induce autosomal recessive Parkinsonism [34–38]. The usual age of onset is between 20 and 40 years. Clinical features consist of dystonia and sleep benefit, which are also characteristic symptoms. Despite affected patients responding well to levodopa, they soon develop motor fluctuations. Conversely, mutations of the PINK1 (PTEN-induced kinase 1) gene at the PARK6 locus induce autosomal recessive Parkinsonism. The age of onset is slightly delayed relative to PARK2, that is, from 32 to 48 years [39]. The affected patients show levodopa-responsive Parkinsonism. PINK1 contains an N-terminal mitochondrial targeting signal and a highly conserved serine/threonine kinase domain, and many missense and nonsense mutations have been reported at the kinase domain [40–44]. In particular, the identification of PINK1 mutations has strongly implicated mitochondrial dysfunction in the pathogenesis of PD [40]. The activity of PINK1 kinase is crucial for mitochondrial maintenance via TRAP phosphorylation [45]. The loss of PINK1 function results in increased vulnerability to various stresses [46–48]. Drosophila models have demonstrated that PINK1 and parkin ensure stable mitochondrial function. Parkin null mutants show severe mitochondrial pathology associated with reduced lifespan, apoptosis, and muscle degeneration [49]. While the PINK1 mutant phenotype can be rescued by parkin gene overexpression [50, 51], the converse does not occur, suggesting that parkin acts downstream of PINK1 in a common pathway to maintain mitochondrial integrity. PINK1 loss-of-function results in reduced mitochondrial membrane potential [52], and the PINK1-parkin pathway is associated with mitochondrial elimination in cultured cells treated with the mitochondrial uncoupler carbonyl cyanide m-chlorophenylhydrazone (CCCP), which causes mitochondrial depolarization [53–58]. The exact mechanism underlying CCCP-induced mitochondrial depolarization, leading to mitochondrial autophagy, has been examined in detail. At steady state, parkin is localized throughout the cytosol but not in the mitochondria. However, parkin was rapidly recruited into the mitochondria when HeLa cells were treated with CCCP [55]. Furthermore, PINK1 recruits parkin from the cytoplasm to the low-membrane potential mitochondria, resulting in the mitochondrial degradation. Interestingly, the ubiquitin-ligase activity of parkin is repressed in the cytoplasm at steadystate; however, PINK1-dependent mitochondrial localization triggered by mitochondrial depolarization liberates the potential enzymatic activity of parkin. While CCCP is well described, its mitochondrial toxic effects provide new insights on the functional interplay between PINK1 and parkin.

4. Accumulation of PINK1 in Damaged Mitochondria

PINK1 is localized in both the mitochondria [40, 59] and the cytoplasm [55, 60]. Treatment with CCCP results in gradual accumulation of PINK1 and translocation of the cytoplasmic
PINK1 to the mitochondria. The subcellular localization of PINK1 is regulated by the mitochondrial membrane potential. Such accumulation may be the first trigger of PINK1-related parkin recruitment. Co-overexpression of PINK1 and parkin results in their colocalization in the mitochondria [61]. Even when these cells were not treated with CCCP, overexpression of PINK1 was associated with translocation of parkin to the cells, together with their mitochondrial aggregation.

Moreover, overexpression of both PINK1 and parkin in the cells resulted in the complete disappearance of the mitochondria. These results suggest that both PINK1 and parkin are indispensable for mitochondrial elimination and that accumulation of PINK1 in the mitochondria results in recruitment of parkin to the mitochondria even in the absence of CCCP [54].

5. PINK1 Kinase Activity Is Essential for Translocation of Parkin

PINK1 is composed of an atypical N-terminal mitochondrial targeting signal and transmembrane domain, kinase domain in the middle, and a conserved C-terminal domain, and deletion of the N-terminal amino acids abolished the mitochondrial localization of PINK1 [62]. Among other mutations, G309D, L347P, and G409V are associated with reduction in PINK1-kinase activity, and a C-terminal domain deletion mutant is associated with PINK1 dysfunction [63, 64]. The G309D/L347P/G409V mutants preserved mitochondrial localization, though their mitochondrial elimination was less compared to cells expressing both the wild-type PINK1 and parkin. When introduced into PINK1-deficient cells, the mutants were unable to complement the localization of parkin [55]. These results indicate that targeting the kinase activity and mitochondrial distribution of PINK1 is important for the mitochondrial recruitment of parkin (Figure 1).

6. PINK1 Deficiency Itself Causes Respiratory Chain Defects

Impaired mitochondrial respiration was observed in the brain of PINK1 null mice [65] although the mechanism linking PINK1 to mitochondrial membrane potential remains to be determined. Amo et al. [66] reported depletion of the mitochondrial membrane potential and cellular ATP levels (~80%) in PINK1-deficient mouse embryonic fibroblasts (MEFs) compared with those in littermate wild-type MEFs. However, loss of PINK1 did not alter mitochondrial proton leak, which reduces the membrane potential in the absence of ATP synthesis. Instead, the authors reported reduced activity of the respiratory chain, which produces the membrane potential by oxidizing substrates using oxygen. The \(H_2O_2\) production rate by PINK1 null mitochondria was lower due to low oxygen consumption rate, while the proportion (\(H_2O_2\) production rate per oxygen consumption rate) was higher. These results suggest that mitochondrial dysfunction in PD is not caused by proton leak, but by a defective respiratory chain. Furthermore, rate of free radical leak was significantly higher in PINK1-deficient MEFs than in wild-type MEFs. Because the differences disappeared with the addition of rotenone (inhibitor of complex I, which inhibits reverse electron flow from coenzyme Q to complex I), conceivably ROS generation enhanced by loss of PINK1 was mostly from complex I. With regard to PINK1-related PD, ROS may be an important factor. The above may also explain why cytoplasmic PINK1 protects neurons against MPTP [47]. Inhibition of complex I itself is associated with increased ROS production [67]. These results are at least in part consistent with those of previous studies, suggesting that MPTP and rotenone induce neuronal cell death by inhibiting complex I activity, leading to a PD-like phenotype [68–70] (Figure 2).

It is not doubtful that ROS generation is harmful to the cells, but the process of cell death is supposed to be slow. The crucial point is how inhibition of complex I
Figure 2: Two mechanisms of mitochondrial toxicity and parkin function. The effect of mitochondrial toxicity is different between CCCP and MPTP. Treatment with CCCP recruits parkin to the mitochondria resulting in mitophagy to keep mitochondrial integrity. Parkin deficiency is associated with accumulation of damaged mitochondria and accelerated cell death. Treatment with MPTP does not necessarily induce parkin. Parkin may be the sensor of damage-adaptive autophagy.

- **Abbreviations**
  - CCCP: Carbonyl cyanide m-chlorophenylhydrazone
  - DAT: Dopamine transporter
  - MEFs: Mouse embryonic fibroblasts
  - MPTP: 1-methyl-4-phenyl-tetrahydropyridine
  - PD: Parkinson's disease
  - PINK1: PTEN-induced putative kinase1
  - ROS: Reactive oxygen species
  - SN: Substantia nigra.

7. Conclusion

Cell death of dopaminergic neurons is due to a combination of exogenous stress and genetic predisposition. The discovery of PD genes has provided important insight including an understanding of PINK1-parkin mediated mitophagy. Furthermore, mitochondrial toxins provided crucial clues: (1) CCCP directly affects mitochondrial dysfunction and induces mitophagy; (2) MPTP toxicity seems to alter ROS generation rather than mitochondrial depolarization. The effects of mitochondrial toxins do not seem to be a one-way manner. The information is available for understanding the pathogenesis in PD. Here, we touched on the fringes of molecular mechanisms of PINK1-parkin-mediated mitophagy. Further research will elucidate how this quality control system applies to neurons.

References


[35] N. Abbá, C. B. Lücking, C. Ricard et al., “A wide variety of mutations in the parkin gene are responsible for autosomal...


Parkinson’s Disease

... by oxidative modification and induces aggregation of oxidized proteins in SH-SY5Y cells,” *Journal of Neuroscience Research*, vol. 74, no. 4, pp. 589–597, 2003.


Submit your manuscripts at http://www.hindawi.com